Market Overview - The Shanghai Composite Index opened slightly lower, while the Shenzhen Component Index, ChiNext Index, and STAR Market Index opened higher by 0.17%, 0.34%, and 0.35% respectively [1] - The Shanghai Composite Index is currently at 4138.65, down by 0.11% [2] - The Shenzhen Component Index is at 14194.11, up by 24.71 points or 0.17% [2] - The ChiNext Index is at 3333.17, up by 11.28 points or 0.34% [2] - The STAR Market Index is at 1812.33, up by 6.31 points or 0.35% [2] Sector Performance - AI applications and commercial aerospace themes experienced a pullback, while sectors such as memory storage, ultra-high voltage, medical services, precious metals, and AI wearable concepts were active [2] - Debon Securities resumed trading with a limit-up, as the company plans to voluntarily terminate its stock listing through a shareholder resolution [2] Company Highlights - Baiwei Storage opened over 9% higher, with a forecasted net profit increase of 427.19% to 520.22% year-on-year for 2025 [3][4] - Debon Securities saw a limit-up price of 15.44, reflecting a significant market interest following its announcement [3] Hong Kong Market - The Hang Seng Index opened 0.46% higher, with the Hang Seng Tech Index rising by 0.42% [4][5] - Notable gainers among constituent stocks include Haidilao, which rose over 5%, and Nongfu Spring, Hansoh Pharmaceutical, and China Biologic Products, which increased by over 3% [4][5]

Market Overview - The A-share market opened with a slight decline in the Shanghai Composite Index, while the Shenzhen Component Index, ChiNext Index, and Sci-Tech Innovation Board Index opened higher by 0.17%, 0.34%, and 0.35% respectively [3][4] - The market showed active trading in sectors such as memory storage, ultra-high voltage, medical services, precious metals, and AI wearable technology, while AI applications and commercial aerospace themes experienced a pullback [4] Individual Stocks - Debon Securities resumed trading with a limit-up increase, as the company plans to voluntarily terminate its stock listing through a shareholder resolution [5] - Baiwei Storage opened over 9% higher, with the company announcing a projected net profit increase of 427.19% to 520.22% year-on-year for 2025 [6][7] Hong Kong Market - The Hong Kong stock market opened with the Hang Seng Index rising by 0.46% and the Hang Seng Tech Index increasing by 0.42%. Notable gainers included Haidilao, which rose over 5%, and other companies like Nongfu Spring, Hansoh Pharmaceutical, and China Biologic Products, which saw increases of over 3% [8][9]

Market Overview - The A-share market opened with a slight decline in the Shanghai Composite Index, while the Shenzhen Component Index, ChiNext Index, and STAR Market Index opened higher by 0.17%, 0.34%, and 0.35% respectively [2][3] - The market saw active trading in sectors such as memory chips, ultra-high voltage, medical services, precious metals, and AI wearable concept stocks [3] Company Highlights - Debon Securities resumed trading with a limit-up increase, as the company plans to voluntarily terminate its stock listing through a shareholder resolution [3] - Baiwei Storage opened over 9% higher after announcing a projected net profit increase of 427.19% to 520.22% year-on-year for 2025 [5] Hong Kong Market - The Hang Seng Index opened up by 0.46%, with the Hang Seng Tech Index rising by 0.42% [6] - Notable gainers among constituent stocks included Haidilao, which rose over 5%, and Nongfu Spring, Hansoh Pharmaceutical, and China Biologic Products, which increased by over 3% [6]

Core Viewpoint - The southbound capital flow into the Hong Kong stock market reached a record net inflow of 1,404.844 billion HKD in 2025, continuing into 2026 with a cumulative net inflow of 41.296 billion HKD as of January 13, 2026, indicating strong market performance driven by this influx [1][2]. Group 1: Southbound Capital Flow - In 2025, southbound capital became the largest source of incremental funds for the Hong Kong stock market, with a total net inflow of 1,404.844 billion HKD, setting a record for annual net inflow [2]. - As of January 13, 2026, there were 6 out of 7 trading days with net inflows, totaling 41.296 billion HKD since the beginning of the year [2]. - The number of shares held by southbound capital increased to 5,643.75 billion shares, with a market value of 6.33 trillion HKD, reflecting a growth of 0.19 trillion HKD since the start of 2026 [2]. Group 2: Market Performance - The Hang Seng Index rose over 4% and the Hang Seng Technology Index increased over 6% since the beginning of 2026, with more than 60% of stocks in the index with a market capitalization exceeding 1 trillion HKD showing an average increase of over 3% [1][5]. - The healthcare, materials, and conglomerates sectors led the market with increases of 15.46%, 12.86%, and 7.62% respectively, while only the telecommunications sector saw a decline of 0.49% [5][6]. - Major stocks such as Tencent Holdings and Alibaba-W saw significant increases, with Tencent rising 4.76% and Alibaba increasing 11.97% since the start of 2026 [6]. Group 3: Investment Outlook - Analysts predict that the southbound capital flow will continue to increase, driven by the low allocation of mainland investors in Hong Kong stocks and the trend of retail funds flowing into the market through ETFs [4]. - The market is expected to benefit from the "14th Five-Year Plan" and the dual easing of fiscal and monetary policies from major economies, with a focus on technology innovation and consumption themes [7][8]. - Five long-term investment directions are suggested: technology sectors including AI, healthcare, resource sectors benefiting from inflation, essential consumer sectors, and industries benefiting from RMB appreciation [8].

药明康德涨7.852%，药明生物涨5.588%，石药集团涨3.700%，阿里巴巴-W涨3.500%，翰森制药涨 3.494%， 中国人寿涨3.450%，恒基地产涨2.922%。 ...

Group 1 - The core viewpoint of the news highlights the strong performance of the innovative pharmaceutical sector, with the CSI Hong Kong Stock Connect Innovative Drug Index rising by 2.08% as of January 13, 2026, driven by significant gains in stocks such as Rongchang Bio (+9.38%), WuXi AppTec (+7.67%), and Tigermed (+7.66) [1] - Eight departments jointly issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'," emphasizing AI in drug development, AI-enabled pharmaceutical supply chains, surgical robots, and intelligent diagnostic systems as key development areas, with a goal to cultivate 2-3 ecosystem-leading enterprises by 2027 [1] - The integration of AI and healthcare is seen as a clear trend, with hardware companies represented by brain-computer interfaces and surgical robots expected to benefit from policy support and technological advancements [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Innovative Drug Index include WuXi Biologics, BeiGene, Innovent Biologics, and others, accounting for a total of 71.36% of the index [2] - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest closely tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which includes stocks involved in innovative drug research and development, as well as services for pharmaceutical companies [2] - Investors without stock accounts can access the opportunities in the Hong Kong innovative drug industry through the Hong Kong Stock Connect Innovative Drug ETF linked fund [2]

Group 1 - The core viewpoint of the news highlights the positive performance of the innovative drug sector in the stock market, with significant gains in individual stocks and ETFs [1][3] - The new national medical insurance drug catalog will be implemented on January 1, 2026, adding 114 new drugs, including 50 Class 1 new drugs, marking a record high in both quantity and proportion [2] - The commercial insurance catalog will include 19 high-value innovative drugs, addressing accessibility issues for high-value innovative treatments [2] Group 2 - The collaboration between domestic innovative drug companies and multinational corporations continues, with 49 outbound transactions totaling over $39 billion since October last year [3] - The market is entering a peak season for business development (BD) and data disclosures, coinciding with the JPM conference and the upcoming annual report cycle [3] - The Hong Kong Stock Connect Innovative Drug ETF (520970) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks accounting for over 71.95% of the total weight [3]

Market Performance - The Hang Seng Technology Index increased by 0.38% and the Hang Seng Index rose by 1.01% [1] - The Hong Kong Technology ETF (159751) gained 1.38%, while the Hang Seng Hong Kong Stock Connect ETF (159318) increased by 1.0% [1] Sector Performance - The life sciences tools and healthcare technology sectors showed the highest gains [1] - Conversely, the passenger airline and communication equipment sectors experienced the largest declines [1] Individual Stock Performance - BBSB International surged over 66% [1] - Zhaoyi Innovation rose by 39.75%, WuXi AppTec increased by 7.94%, CSPC Pharmaceutical Group gained 5.5%, Zijin Mining International rose by 5.49%, Ganfeng Lithium increased by 4.73%, WuXi Biologics rose by 4.52%, and Hansoh Pharmaceutical gained 4.13% [1] - Nanjing Panda Electronics fell by 5.47%, and Goldwind Technology dropped by 6.64% [1] - Ark Health gained 37.55%, and Haotian International Construction Investment rose by 17.86% [1]

每经AI快讯，翰森制药(03692.HK)午前涨超4%，截至发稿，涨3.64%，报42.12港元，成交额9762.23万 港元。 ...

Core Viewpoint - Hansoh Pharmaceutical (03692) has received approval from the National Medical Products Administration (NMPA) for its innovative drug Amelot (Ametinib Mesylate Tablets) to be used in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. This marks the fifth indication approved for Amelot [1][1][1]. Group 1 - Hansoh Pharmaceutical's stock rose over 4% and was trading at HKD 42.12 with a transaction volume of HKD 97.62 million at the time of reporting [1][1][1]. - The newly approved indication for Amelot targets adult patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [1][1][1]. Group 2 - Recent research published in the prestigious oncology journal Lancet Oncology indicates that Amelot significantly improves disease-free survival (DFS) in patients with completely resected stage II-III B EGFR-mutant NSCLC, demonstrating good safety [1][1][1].